Related references
Note: Only part of the references are listed.Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
Melinda L. Telli et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
Nihat Kalay et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
E Tan-Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effect of carvedilol on survival in severe chronic heart failure.
M Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)